NCT04358185View on ClinicalTrials.gov

Itacitinib in Advanced Hepatocellular Carcinoma

PHASE1UnknownINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

Itacitinib (INCB039110)

Novel and small molecule selective inhibitor of JAK1

Trial Locations (1)

W12 0HS

Imperial College Healthcare NHS Trust, London

Sponsors

Collaborators (1)

Incyte Biosciences UK Ltd

All Listed Sponsors

collaborator

Incyte Biosciences UK Ltd

UNKNOWN

lead

Imperial College London

OTHER